Skip to main content

Table 1 Patient characteristics

From: Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy

Average age and range (years)

Pre-treatment PSA (ng/ml)

Gleason score

Tumor stage

Average target volume (cm3)

Body-mass-index (BMI)

Comorbidity

71.9

(48–88)

 < 10: 20 patients

10–20: 12 patients

6 (3 + 3):

9 patients

7 (3 + 4):

23 patients

T1c:

15 patients

T2a-T2c:

17 patients

65.3 ± 26.3 (prostate)

18.3 ± 5.5 (seminal vesicles)

26.6 ± 2.8

Diabetes: 6

Hypertension: 18

Cardiovascular condition: 9